9.57

2.35% -0.23

Vir Biotechnology Inc (VIR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt VIR? Forum Prognose

Schlusskurs vom Vortag:

$9.80

Offen:

$9.9

24-Stunden-Volumen:

706.89K

Relative Volume:

0.35

Marktkapitalisierung:

$1.32B

Einnahmen:

$62.04M

Nettoeinkommen (Verlust:

$-533.34M

KGV:

-2.4413

EPS:

-3.92

Netto-Cashflow:

$-473.07M

1W Leistung:

-0.83%

1M Leistung:

-8.16%

6M Leistung:

+10.38%

1J Leistung:

-5.34%

1-Tages-Spanne:

$9.51

$9.93

1-Wochen-Bereich:

$9.51

$9.98

52-Wochen-Spanne:

$6.56

$14.45

Vir Biotechnology Inc Stock (VIR) Company Profile

Firmenname

Vir Biotechnology Inc

Sektor

Healthcare (1169)

Branche

Biotechnology (678)

Telefon

415-906-4324

Adresse

1800 OWENS STREET, SAN FRANCISCO, CA

Mitarbeiter

587

Twitter

@Vir_Biotech

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

VIR's Discussions on Twitter

Vergleichen Sie VIR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VIR Vir Biotechnology Inc	9.57	1.32B	62.04M	-533.34M	-473.07M	-3.92
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-29	Herabstufung	JP Morgan	Overweight → Neutral
2023-09-08	Herabstufung	BofA Securities	Buy → Neutral
2023-03-06	Hochstufung	JP Morgan	Neutral → Overweight
2023-02-21	Hochstufung	Goldman	Neutral → Buy
2023-01-27	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2022-09-14	Eingeleitet	SVB Leerink	Outperform
2022-09-09	Eingeleitet	Morgan Stanley	Underweight
2022-03-03	Hochstufung	Robert W. Baird	Underperform → Neutral
2021-12-21	Herabstufung	Robert W. Baird	Neutral → Underperform
2021-10-25	Hochstufung	JP Morgan	Underweight → Neutral
2021-09-22	Herabstufung	Goldman	Buy → Neutral
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-01-27	Herabstufung	JP Morgan	Neutral → Underweight
2021-01-20	Bestätigt	H.C. Wainwright	Buy
2020-10-05	Eingeleitet	BofA Securities	Buy
2020-09-14	Hochstufung	Goldman	Neutral → Buy
2020-09-11	Hochstufung	JP Morgan	Underweight → Neutral
2020-08-20	Eingeleitet	Needham	Buy
2020-03-19	Herabstufung	JP Morgan	Neutral → Underweight
2020-03-13	Herabstufung	Goldman	Buy → Neutral
2020-02-27	Herabstufung	Robert W. Baird	Neutral → Underperform
2020-02-04	Herabstufung	JP Morgan	Overweight → Neutral
2019-11-14	Eingeleitet	Robert W. Baird	Neutral
2019-11-05	Eingeleitet	Barclays	Overweight
2019-11-05	Eingeleitet	Cowen	Outperform
2019-11-05	Eingeleitet	Goldman	Buy
2019-11-05	Eingeleitet	JP Morgan	Overweight

Alle ansehen

Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten

Feb 20, 2025

(VIR) Trading Advice - Stock Traders Daily

Feb 20, 2025

Feb 19, 2025

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference - BioSpace

Feb 19, 2025

Vir Biotechnology director George Scangos sells $107,575 in stock By Investing.com - Investing.com South Africa

Feb 19, 2025

Vir Biotechnology director George Scangos sells $107,575 in stock - Investing.com

Feb 19, 2025

Will Vir Biotechnology Reveal New Strategic Initiatives? Key Conference Appearance Ahead - StockTitan

Feb 19, 2025

Feb 18, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Empowered Funds LLC - MarketBeat

Feb 18, 2025

Feb 17, 2025

Brent Sabatini Sells 1,562 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock - MarketBeat

Feb 17, 2025

Feb 16, 2025

Vir Biotechnology SVP sells shares for $14,291 - MSN

Feb 16, 2025

Xencor, Inc. Enters License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat Covid-19 with Vir Biotechnology - Marketscreener.com

Feb 16, 2025

Feb 15, 2025

Vir Biotechnology (NASDAQ:VIR) Shares Down 4.8%Here's Why - MarketBeat

Feb 15, 2025

Feb 14, 2025

Vir Biotechnology SVP sells shares for $14,291 By Investing.com - Investing.com Nigeria

Feb 14, 2025

Vir Biotechnology Officer Sells Shares to Cover Tax Obligations - TradingView

Feb 14, 2025

Feb 12, 2025

abrdn plc Buys Shares of 363,161 Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat

Feb 12, 2025

Vir Biotechnology Sets Stage for Major Corporate Strategy Reveal with Q4 Earnings - StockTitan

Feb 12, 2025

Feb 10, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Feb 10, 2025

Feb 09, 2025

After a year of 7.8% returns, Vir Biotechnology, Inc.'s (NASDAQ:VIR) share price drop last week may have less of an impact on institutional investors - Simply Wall St

Feb 05, 2025

Feb 04, 2025

NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer - BioSpace

Feb 04, 2025

Feb 03, 2025

HC Wainwright Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat

Feb 03, 2025

Feb 02, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Short Interest Update - MarketBeat

Feb 02, 2025

Jan 31, 2025

Vir Biotechnology appoints new Chief Technical Officer By Investing.com - Investing.com Australia

Jan 31, 2025

Jan 30, 2025